Profile data is unavailable for this security.
About the company
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
- Revenue in USD (TTM)16.94m
- Net income in USD-122.54m
- Incorporated2004
- Employees55.00
- LocationCara Therapeutics Inc400 Atlantic Street, Suite 500STAMFORD 06901United StatesUSA
- Phone+1 (203) 406-3700
- Fax+1 (203) 567-1510
- Websitehttps://www.caratherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Guardion Health Sciences Inc | 12.06m | -5.12m | 12.29m | 9.00 | -- | 3.60 | -- | 1.02 | -4.00 | -4.00 | 9.49 | 2.66 | 0.9718 | 2.63 | 5.96 | 1,340,280.00 | -41.26 | -77.90 | -47.92 | -86.55 | 43.43 | 42.45 | -42.46 | -176.93 | 6.49 | -4.24 | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
Allied Corp | 98.65k | -7.73m | 14.19m | -- | -- | -- | -- | 143.84 | -0.0776 | -0.0776 | 0.001 | -0.0726 | 0.0234 | 1.55 | 0.5284 | -- | -183.13 | -- | -- | -- | -1,452.53 | -- | -7,835.49 | -- | 0.0382 | -8.18 | -- | -- | -56.46 | -- | 31.30 | -- | -- | -- |
Talphera Inc | 651.00k | -14.31m | 15.05m | 15.00 | -- | 0.9215 | -- | 23.12 | -0.8945 | -0.8863 | 0.0368 | 0.9612 | 0.0237 | -- | -- | 43,400.00 | -51.96 | -22.60 | -67.70 | -28.55 | -- | -- | -2,197.39 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 16.00m | 1.00 | -- | 0.0893 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
Aytu Biopharma Inc | 93.76m | -13.68m | 16.13m | 150.00 | -- | 0.4885 | -- | 0.172 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
Polypid Ltd | 0.00 | -24.25m | 16.60m | 59.00 | -- | 2.32 | -- | -- | -12.35 | -12.35 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -84.94 | -76.92 | -120.03 | -89.61 | -- | -- | -- | -- | -- | -28.72 | 0.5498 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
Pharmacyte Biotech Inc | 0.00 | -14.82m | 16.75m | 2.00 | -- | 0.538 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
Nexgel Inc | 4.74m | -3.20m | 19.55m | 19.00 | -- | 4.08 | -- | 4.13 | -0.5535 | -0.5535 | 0.8208 | 0.7688 | 0.4428 | 3.24 | 8.46 | 249,263.20 | -30.72 | -44.61 | -39.92 | -56.19 | 20.14 | 5.02 | -69.38 | -180.98 | 1.41 | -- | 0.1819 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
Aptorum Group Ltd | 431.38k | -2.82m | 19.86m | 3.00 | -- | 0.757 | -- | 46.04 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
Cara Therapeutics Inc | 16.94m | -122.54m | 20.36m | 55.00 | -- | 0.6831 | -- | 1.20 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Cumberland Pharmaceuticals, Inc. | 38.83m | -8.42m | 20.86m | 91.00 | -- | 0.7572 | -- | 0.5373 | -0.596 | -0.596 | 2.72 | 1.94 | 0.4542 | 0.8812 | 3.08 | 426,654.70 | -9.83 | -7.03 | -14.07 | -9.52 | 83.54 | 79.95 | -21.65 | -17.64 | 1.21 | -24.56 | 0.3717 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
TherapeuticsMD Inc | 1.20m | -6.20m | 21.10m | 1.00 | -- | 0.7362 | -- | 17.60 | -0.58 | -0.6955 | 0.1103 | 2.49 | 0.0236 | -- | 0.4556 | 1,199,000.00 | -12.19 | -53.35 | -16.34 | -111.61 | 73.89 | 86.67 | -516.93 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
Bio Essence Corp | 551.51k | -812.66k | 25.47m | 12.00 | -- | -- | -- | 46.18 | -0.0225 | -0.0157 | 0.015 | -0.0378 | 0.4912 | -- | 1.53 | 45,959.17 | -72.37 | -46.34 | -- | -- | 31.29 | 33.89 | -147.35 | -111.21 | -- | -47.73 | 3.39 | -- | -11.27 | -10.94 | -52.03 | -- | -48.19 | -- |
Acasti Pharma Inc | 0.00 | -12.85m | 25.94m | 32.00 | -- | 0.4202 | -- | -- | -1.46 | -1.46 | 0.00 | 6.57 | 0.00 | -- | -- | -- | -16.86 | -31.68 | -17.45 | -33.95 | -- | -- | -- | -56,271.43 | -- | -6.18 | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
Rapid Micro Biosystems Inc | 23.10m | -51.90m | 28.72m | 193.00 | -- | 0.2706 | -- | 1.24 | -1.20 | -1.20 | 0.5355 | 2.48 | 0.1535 | 1.37 | 4.34 | 119,663.20 | -34.49 | -- | -38.20 | -- | -22.59 | -- | -224.73 | -- | 5.62 | -- | 0.0028 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.06m | 5.60% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.44m | 4.47% |
Disciplined Growth Investors, Inc.as of 31 Mar 2024 | 1.82m | 3.32% |
Chescapmanager LLCas of 31 Mar 2024 | 1.70m | 3.11% |
Farallon Capital Management LLCas of 31 Mar 2024 | 1.56m | 2.85% |
Renaissance Technologies LLCas of 31 Mar 2024 | 1.33m | 2.44% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.02m | 1.87% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.00m | 1.83% |
Stifel Nicolaus & Co., Inc. (Investment Management)as of 31 Mar 2024 | 741.37k | 1.36% |
Millennium Management LLCas of 31 Mar 2024 | 661.83k | 1.21% |